RADIUS HEALTH, INC. (NASDAQ:RDUS) Files An 8-K Results of Operations and Financial Condition

RADIUS HEALTH, INC. (NASDAQ:RDUS) Files An 8-K Results of Operations and Financial Condition
Item 2.02

Story continues below

Results of Operations and Financial Condition.

On August 3, 2017, Radius Health, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2017. A copy of the press release is attached hereto as Exhibit 99.1.

The information contained in this Form 8-K (including Exhibit 99.1) is being furnished and shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as expressly provided by specific reference in such a filing.

Item 2.02

Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.



Press Release dated August 3, 2017.

Radius Health, Inc. Exhibit
EX-99.1 2 rdus-ex991_18.htm EX-99.1 rdus-ex991_18.htm Exhibit 99.1   Radius Health Reports Second Quarter 2017 Financial and Operating Results and Provides Business Update   2Q’17 financial results reflect the first 4 weeks of TYMLOS sales in the U.S.   Managed care contracts in place for coverage of over 130 million lives for TYMLOS™ (68% of all Commercial and 28% of Medicare) point to strong and early acceptance in the US with our sales team having already reached over 90% of the top 7,…
To view the full exhibit click here


Radius Health, Inc. is a biopharmaceutical company focused on developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. Its product candidate, the investigational drug abaloparatide for subcutaneous injection, has completed Phase III development for use in the reduction of fracture risk in postmenopausal women with osteoporosis. Its clinical pipeline also includes an investigational abaloparatide transdermal patch for use in osteoporosis and the investigational drug RAD1901 for use in hormone-driven and hormone-resistant breast cancer, and vasomotor symptoms in postmenopausal women. Its preclinical pipeline includes RAD140, a non-steroidal, selective androgen receptor modulator (SARM) under investigation for use in cancer.

An ad to help with our costs